ClinicalTrials.gg
Active, not recruitingNCT07646795NOVAMAG-2024Updated Nov 6, 2026

Alveolar Ridge Reconstruction in Post-extraction Sites Using a Magnesium Resorbable Membrane. An Explorative Study

An interventional study of NOVAMag® in Bone Augmentation and Alveolar Ridge Augmentation, sponsored by Martina Stefanini. Active, not recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Martina Stefanini · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 6 months after the study started (first participant enrolled Nov 2024, registered Jun 2026).
Updated Nov 6, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 213 studies in Pain with a site in Italy — 35 open to participants now, 41 under way, 1 of them phase 3. Pain · Italy.

Enrollment
150th of 156
10 · median 80
Started
2024
with 19 others
No phase
102 of 213
14 open now
Primary completion
2026-11
later than 26 of 40 live
Registered
207th of 213
by date

Among the 213 studies in Pain with a site in Italy, this one is the 150th largest by enrollment of the 156 interventional ones that give a count, is one of 20 that started in 2024, is one of 102 with no phase, reaches primary completion later than 26 of the 40 other live ones, and was the 207th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

35 of the 213 studies in Pain with a site in Italy are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 213 studies in Pain with a site in Italy, or all of them as a file.
02

Study summary

When a tooth is removed, the surrounding bone and gum tissue naturally shrink over time. This shrinkage can make it harder to place a dental implant later and may affect the appearance of the smile. To reduce bone loss after extraction, surgeons can fill the socket with a bone substitute material and cover it with a protective membrane.

This study tests a new type of membrane made from magnesium metal (NOVAMag®). Unlike standard resorbable membranes, the magnesium membrane is rigid enough to hold its shape and protect the bone graft even in severely damaged sockets - similar to non-resorbable membranes. Unlike non-resorbable membranes, however, it dissolves on its own within about 16 weeks, so no second surgery is needed to remove it. As it breaks down, it releases magnesium ions that may also help stimulate new bone formation.

This study will enroll 10 adult patients who need a tooth removed and plan to have a dental implant placed afterward. After extraction, the socket will be filled with a bovine bone substitute, covered with the magnesium membrane, and sealed with a collagen membrane on top. Patients will be followed for up to 19 months. At 6 months, a CT scan will be used to measure how much bone has been preserved. At the time of implant placement, a small bone sample will be analyzed in the laboratory to assess new bone formation. Patients will also complete questionnaires about pain and quality of life, and the healing of the surgical site will be monitored at each visit.

The goal is to find out whether this magnesium membrane can effectively preserve bone after tooth extraction, reduce the need for additional bone grafting before implant placement, and offer a less invasive option for patients.

Read the detailed description

Here is the Detailed Description rewritten following ClinicalTrials.gov guidelines - technical but not duplicating eligibility criteria, outcome measures, or the brief summary:

DETAILED DESCRIPTION Background and Rationale Alveolar ridge reconstruction (ARR) in post-extraction sites with extensive bony wall damage (Class III-IV sockets) represents a significant clinical challenge. Current evidence supports the use of bone substitutes combined with barrier membranes; however, available options present trade-offs. Resorbable collagen membranes lack the mechanical rigidity needed to maintain space in severely compromised defects, while non-resorbable membranes - though structurally stable - carry a higher risk of infection and require a second surgical procedure for removal.

The NOVAMag® membrane (Botiss Biomaterials, Berlin, Germany) is a CE-marked medical device manufactured from pure magnesium metal. It provides mechanical strength comparable to non-resorbable membranes while remaining fully biodegradable. Upon degradation, it releases magnesium ions (Mg²⁺), which are naturally occurring in the human body and have been shown to stimulate cortical bone growth via periosteal stem cells and calcitonin gene-related peptide (CGRP) release from sensory nerve endings. A minor volume of hydrogen gas is also released during degradation, providing slight soft tissue tenting that supports space maintenance. Complete membrane degradation occurs by approximately 16 weeks post-implantation, eliminating the need for surgical removal. Biocompatibility has been previously demonstrated in cardiovascular and orthopedic applications, and preclinical data in a Beagle dog model showed outcomes comparable to collagen membranes for guided bone regeneration.

Study Design This is a no-profit, prospective, single-arm, monocenter pilot interventional study evaluating a post-marketing medical device. The study will be conducted at the Periodontal Unit, Dental Clinic, DIBINEM, University of Bologna, Italy. Given the exploratory nature of the study, no control group is included and no formal hypothesis testing is planned. Ten consecutive eligible patients will be enrolled.

Surgical Procedure All patients undergo cause-related periodontal therapy prior to enrollment until adequate oral hygiene standards are achieved. At baseline, a CBCT scan and intraoral optical scan (3D) are obtained for pre-surgical assessment and reference measurements.

During the surgical session, the compromised tooth is extracted with flap elevation as clinically required. The socket is thoroughly debrided to expose all bony surfaces. The NOVAMag® membrane is then shaped and trimmed to fully cover the bone deficiency. The socket is filled with xenogenic bone substitute (Cerabone plus, Botiss, Germany) up to the crestal bone border. A collagen membrane (Mucoderm, Botiss, Germany) is placed coronally to seal the socket and fixed to the adjacent crestal soft tissues using cross-mattress sutures (6.0 PGA). Intraoperative measurements of alveolar bone dehiscence in height and width, and soft tissue thickness, are recorded.

Postoperative care includes chlorhexidine rinses three times daily until suture removal at 14 days, and antibiotic prophylaxis with Amoxicillin 1g twice daily for 6 days starting the day before surgery (alternative provided in case of allergy).

At 6 months, a second CBCT and intraoral scan are obtained for implant planning (standard of care). During implant placement, bone core biopsies are collected from the drilling waste prior to implant positioning and transferred to 4% formalin solution for histological processing.

Histological and Histomorphometric Analysis Biopsy specimens will be embedded in Technovit 9100 polymer system, dehydrated, and sectioned at 7 µm using a rotation microtome for hard tissue. Sections will be stained with hematoxylin and eosin (H\&E) and Movat Pentachrome. Total area scans will be generated by scanning microscopy (M8, PreciPoint) and analyzed using ImageJ v1.53 to quantify the percentage of new bone formation, residual bone substitute, and connective tissue within the implantation area. Analysis will be performed at Berlin Analytix GmbH (Berlin, Germany), provided free of cost by Botiss Biomaterials.

Statistical Analysis Due to the exploratory and descriptive nature of this pilot study, no formal statistical inference will be drawn. All non-missing data will be analyzed. Quantitative variables will be described by mean, standard deviation, standard error of the mean, median, minimum, maximum, and interquartile range. Qualitative variables will be reported as absolute and relative frequencies. Analysis will be performed using IBM SPSS Statistics v20.

Funding and Agreements Study materials (NOVAMag® membrane, Cerabone plus, Mucoderm) are donated free of cost by Botiss Biomaterials GmbH for the duration of the study and used exclusively per manufacturer's instructions. Participant insurance and histological analysis costs are covered by Botiss Biomaterials GmbH. A formal collaboration agreement is in place.

03

Conditions studied

  • Bone Augmentation
  • Alveolar Ridge Augmentation

Browse trials for

Keywords

  • magnesium
  • postoperative
  • pain,
  • quality of life
  • oral health
  • patient-reported outcome measures
  • wound healing
  • membrane
  • alveolar ridge augmentation
  • BONE AUGMENTATION
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Patients agreeing to participate in the study

      • Age 18 years or older
      • Periodontally healthy (including patients currently in supportive periodontal maintenance therapy) or patients with ongoing periodontal treatment
      • Compromised tooth because of severe periodontitis or root fracture
      • full mouth plaque score \< 20% and full-mouth bleeding score \< 20% at the time of alveolar bone reconstruction

Exclusion criteria

Exclusion Criteria:

    • Heavy smokers (≥10 cigarettes/day)

      • Patients with a history of , radiotherapy, or chemo-therapy for malignancy.
      • Pregnant patients or nursing during the past 6 months.
      • Patients taking medications or having treatments with an effect on mucosal healing in general (e.g., large doses of anti- inflammatory drugs)
      • Uncontrolled medical conditions, presence of systemic diseases or consumption of medications known to alter bone metabolism
      • allergic reactions to bovine bone substitute
      • patients that do not comply with the oral hygiene maintenance program and follow-up visits
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    ID PATIENT

    Single-arm intervention consisting of tooth extraction followed by alveolar ridge reconstruction using: (1) xenogenic bone substitute (bovine-derived, granules) to fill the extraction socket up to the crestal bone border; (2) a resorbable pure magnesium barrier membrane (NOVAMag®) shaped and trimmed to cover the bony defect; and (3) a porcine-derived collagen membrane (Mucoderm®) placed coronally to seal the socket, fixed with cross-mattress sutures (6.0 PGA). Postoperative antibiotic prophylaxis: Amoxicillin 1g orally twice daily for 6 days, starting the day before surgery.

    Device: NOVAMag®

Interventions

  • DeviceNOVAMag®

    Resorbable pure magnesium metal barrier membrane (NOVAMag®, Botiss Biomaterials, Berlin, Germany). Shaped and trimmed intraoperatively to fully cover the bony defect at the post-extraction site. Placed between the bone substitute and the overlying soft tissues to maintain space and support bone regeneration. Degrades completely within approximately 16 weeks without requiring surgical removal. Bovine-derived granular bone substitute (Cerabone plus, Botiss Biomaterials, Berlin, Germany). Used to fill the extraction socket up to the crestal bone border following thorough socket debridement and placement of the magnesium membrane. Porcine-derived acellular collagen matrix (Mucoderm®, Botiss Biomaterials, Berlin, Germany). Placed coronally to seal the socket and prevent exposure of the bone graft and magnesium membrane. Fixed to adjacent crestal soft tissues with cross-mattress sutures (6.0 PGA).

    Also known as: Cerabone plus, Mucoderm®

06

What researchers measure

Primary outcomes

  1. Alveolar Bone Dimensional Changes in Height and Width

    Alveolar bone changes in height (ARH) and width (ARW) measured in mm via CBCT scans at baseline and 6 months after alveolar ridge reconstruction. ARH is measured from the midpoint of the line connecting buccal and lingual/palatal crestal bone to a fixed anatomical reference point. ARW is measured at 1, 3, and 5 mm apical to that midpoint.

    Time frame: Baseline and 6 months after alveolar ridge reconstruction

Secondary outcomes

  1. Soft Tissue Volumetric Changes

    Volumetric changes of buccal and occlusal soft tissues assessed by superimposition of intraoral 3D optical scans (STL files). Outcomes include volume change (mm³), mean surface distance/thickness (mm), and linear dimensional changes from 1 to 7 mm from the soft tissue margin.

    Time frame: Baseline and 6 months after alveolar ridge reconstruction

  2. New Bone Formation

    Histomorphometric analysis of core biopsies obtained during implant site preparation. Outcomes include percentage of new bone formation, residual bone substitute, and connective tissue within the total implantation area.

    Time frame: 6 months after alveolar ridge reconstruction (at implant placement)

  3. Patient-Reported Outcomes

    Patient morbidity assessed via 10mm Visual Analogue Scale (VAS, where the highest means the highest pain) for pain and Oral Health Impact Profile-14 (OHIP-14) questionnaire.

    Time frame: 7 days, 14 days, 1 month, 3 months, and 6 months after surgery

  4. Adverse Device Reactions

    Incidence and nature of adverse events related to the device or procedure, including wound dehiscence, inflammation, swelling, infection, and membrane exposure, recorded in the Case Report Form

    Time frame: From surgery up to 6 months after alveolar ridge reconstruction

07

Study locations

1 site
  • Periodontal Unit, Department of Biomedical and Neuromotor Sciences, UNiversity of Bologna
    Bologna, BO 40125, Italy
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Nov 2026, 24 months after the start.

Of 3,749 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 24 months is above that.

Counting every sponsor, half of 3,848 studies reached it within 10 months; a quarter within 4 and three quarters within 23.

Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2026
First posted
Jun 15, 2026
StartActual
Nov 27, 2024
Primary completionEst.
Nov 27, 2026was Sep 2026
CompletionEst.
Jul 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2026→Nov 27, 2026
Nov 6, 2026
Secondary outcomes
1 description edited
What changed in the outcomes
  • DescriptionPatient-Reported Outcomes: how it is measured was reworded
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Primary completion Sep 2026→Nov 27, 2026
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionPatient-Reported Outcomes: how it is measured was reworded
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07646795
Lead sponsor
Martina Stefanini
Responsible party
Martina Stefanini (PROFESSOR, University of Bologna) — Sponsor-investigator
First posted
Jun 15, 2026
Start date
Nov 27, 2024
Primary completion
Nov 27, 2026 (estimated)
Completion
Jul 2027 (estimated)
Last update
Nov 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion